# Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

> **NCT00053703** · PHASE4 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 116 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Olanzapine (enrollment closed in this treatment)
- **DRUG:** Molindone

## Key facts

- **NCT ID:** NCT00053703
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2014-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053703, "Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00053703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*